Sandbox Reserved 1127
From Proteopedia
(Difference between revisions)
| Line 12: | Line 12: | ||
== Structural highlights == | == Structural highlights == | ||
| - | PDE5 is a | + | PDE5 is a homodimeric protein of 875 amino acids long. This protein is composed of several important domains: |
| + | pol-GLY (10-24 amino acids) in Ntermini (structural importance). | ||
| + | GAFA (164-314 amino acids) | ||
| + | GAFB (346-503 amino acids) | ||
| + | Catalytic domain (588-853 amino acids) in Ctermini involved in cGMP hydrolysis. | ||
| + | The full structure of PDE5 has not been crystallized contrary to this of isolated domains of the protein. | ||
| + | GAFA and GAFB are homologous domains and allosteric binding site of cGMP. | ||
==Catalytic activity== | ==Catalytic activity== | ||
| + | PDE5 is a phosphodiesterase. cGMP could bind the catalytic domain thanks to hydrogen bonds made with Gln775 and Gln817 and coordination bonds made with Zn2+ and Mg2+ in the catalytic site. To see these interactions, report to Sildenafil in Inhibitors and medical application. | ||
| + | cGMP is hydrolyzed in GMP. The catalytic chemical reaction deals with breaking a phosphodiester bound in cGMP between the 3'O of the guanoside and the phosphate of cGMP: cGMP + H20 => GMP. | ||
Some residues could be affected by post traductional modifications : | Some residues could be affected by post traductional modifications : | ||
| - | + | phosphorylation : S60, S86, S92, S102, S104, S108, T111, T127, T137, S869. | |
| - | + | acylation : K364. | |
| - | + | ubiquitinylation : K714. | |
| - | + | ||
The ubiquitinylation of <scene name='71/719868/K714/1'>K714</scene> (in fushia) and the phosphorylation of are involved in the binding of cGMP to PDE5 catalytic domain. | The ubiquitinylation of <scene name='71/719868/K714/1'>K714</scene> (in fushia) and the phosphorylation of are involved in the binding of cGMP to PDE5 catalytic domain. | ||
== Inhibitors and medical application == | == Inhibitors and medical application == | ||
| - | If an inhibitor binds instead of cGMP, cGMP concentration increases and the stimulus continues. PDE5 inhibition is particulary used for erectile disfunction. | ||
| - | Sildenafil or VIagra is an inhibitor of PDE5. | ||
| - | + | Inhibitors of PDE5 prevent cGMP from binding the catalytic site by competititve inhibition. They have more affinity for this domain than cGMP. | |
| + | Sildenafil (active substance of Viagra) binds to PDE5 catalytic domain through: | ||
| + | hydrogen bonds made between Gln775 and Gln817 of PDE5 (green) and <scene name='71/719868/Sildenafil/1'>Sildenafil</scene> (red) | ||
| + | coordination bond made with | ||
| + | coordination made with | ||
| + | |||
==Allosteric activation== | ==Allosteric activation== | ||
Revision as of 16:57, 30 January 2016
| This Sandbox is Reserved from 15/12/2015, through 15/06/2016 for use in the course "Structural Biology" taught by Bruno Kieffer at the University of Strasbourg, ESBS. This reservation includes Sandbox Reserved 1120 through Sandbox Reserved 1159. |
To get started:
More help: Help:Editing |
Human PDE5
| |||||||||||
